Loading cancer entity…
Loading cancer entity…
Clinical trials
6 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03025256 | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | active not recruiting | Phase 1 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07414979 | Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma | not yet recruiting | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 |
| NCT03175432 | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases | active not recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06926803 | A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases | active not recruiting | — | 500 | Qiming WangOTHER_GOV | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06417710 | Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis(NANO-LM) | recruiting | — | 200 | University of ZurichOTHER | 3 | May 16, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials